Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
Clayton Dubilier & Rice made it a condition for banks to commit more than €1 billion ($1.1 billion) of debt to fund a part of ...
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website ...
AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot ...